Annual EBIT
-$314.49 M
+$21.04 M+6.27%
31 December 2023
Summary:
Allogene Therapeutics annual earnings before interest & taxes is currently -$314.49 million, with the most recent change of +$21.04 million (+6.27%) on 31 December 2023. During the last 3 years, it has fallen by -$56.25 million (-21.78%). ALLO annual EBIT is now -74.53% below its all-time high of -$169.74 million.ALLO EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBIT
-$66.19 M
+$249.00 K+0.37%
30 September 2024
Summary:
Allogene Therapeutics quarterly earnings before interest & taxes is currently -$66.19 million, with the most recent change of +$249.00 thousand (+0.37%) on 30 September 2024. Over the past year, it has dropped by -$3.91 million (-6.27%). ALLO quarterly EBIT is now -3977.74% below its all-time high of $1.71 million, reached on 31 December 2021.ALLO Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBIT
-$275.14 M
-$3.91 M-1.44%
30 September 2024
Summary:
Allogene Therapeutics TTM earnings before interest & taxes is currently -$275.14 million, with the most recent change of -$3.91 million (-1.44%) on 30 September 2024. Over the past year, it has increased by +$63.24 million (+18.69%). ALLO TTM EBIT is now -10494.69% below its all-time high of -$2.60 million, reached on 31 March 2018.ALLO TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ALLO EBIT Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +6.3% | -6.3% | +18.7% |
| 3 y3 years | -21.8% | +14.8% | -9.5% |
| 5 y5 years | -51.0% | -20.3% | -63.7% |
ALLO EBIT High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -74.5% | +6.3% | -3977.7% | +33.2% | -52.7% | +23.3% |
| 5 y | 5 years | -74.5% | +6.3% | -3977.7% | +33.2% | -63.7% | +23.3% |
| alltime | all time | -74.5% | +6.3% | -3977.7% | +51.0% | <-9999.0% | +23.3% |
Allogene Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$66.19 M(-0.4%) | -$275.14 M(+1.4%) |
| June 2024 | - | -$66.44 M(-4.4%) | -$271.24 M(-4.9%) |
| Mar 2024 | - | -$69.50 M(-4.8%) | -$285.34 M(-9.4%) |
| Dec 2023 | -$314.49 M(-6.3%) | -$73.00 M(+17.2%) | -$314.92 M(-6.9%) |
| Sept 2023 | - | -$62.29 M(-22.7%) | -$338.38 M(-5.6%) |
| June 2023 | - | -$80.54 M(-18.7%) | -$358.58 M(+1.1%) |
| Mar 2023 | - | -$99.09 M(+2.7%) | -$354.64 M(+5.7%) |
| Dec 2022 | -$335.54 M(+86.2%) | -$96.46 M(+16.9%) | -$335.54 M(+41.4%) |
| Sept 2022 | - | -$82.49 M(+7.7%) | -$237.37 M(+2.1%) |
| June 2022 | - | -$76.59 M(-4.2%) | -$232.55 M(+2.5%) |
| Mar 2022 | - | -$79.99 M(-4786.1%) | -$226.98 M(+26.0%) |
| Dec 2021 | -$180.19 M | $1.71 M(-102.2%) | -$180.19 M(-28.3%) |
| Sept 2021 | - | -$77.67 M(+9.3%) | -$251.26 M(+4.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| June 2021 | - | -$71.03 M(+113.9%) | -$241.63 M(+3.4%) |
| Mar 2021 | - | -$33.20 M(-52.1%) | -$233.76 M(-9.5%) |
| Dec 2020 | -$258.24 M(+27.8%) | -$69.36 M(+1.9%) | -$258.24 M(+1.9%) |
| Sept 2020 | - | -$68.04 M(+7.7%) | -$253.46 M(+5.4%) |
| June 2020 | - | -$63.16 M(+9.5%) | -$240.43 M(+7.7%) |
| Mar 2020 | - | -$57.68 M(-10.7%) | -$223.23 M(+10.5%) |
| Dec 2019 | -$202.01 M(-3.0%) | -$64.58 M(+17.4%) | -$202.01 M(+20.2%) |
| Sept 2019 | - | -$55.01 M(+19.7%) | -$168.06 M(+9.7%) |
| June 2019 | - | -$45.96 M(+26.1%) | -$153.19 M(-36.8%) |
| Mar 2019 | - | -$36.46 M(+19.1%) | -$242.24 M(+16.3%) |
| Dec 2018 | -$208.26 M | -$30.63 M(-23.7%) | -$208.37 M(+17.2%) |
| Sept 2018 | - | -$40.14 M(-70.3%) | -$177.75 M(+29.2%) |
| June 2018 | - | -$135.01 M(+5098.8%) | -$137.61 M(+5198.8%) |
| Mar 2018 | - | -$2.60 M | -$2.60 M |
FAQ
- What is Allogene Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Allogene Therapeutics?
- What is Allogene Therapeutics annual EBIT year-on-year change?
- What is Allogene Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Allogene Therapeutics?
- What is Allogene Therapeutics quarterly EBIT year-on-year change?
- What is Allogene Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Allogene Therapeutics?
- What is Allogene Therapeutics TTM EBIT year-on-year change?
What is Allogene Therapeutics annual earnings before interest & taxes?
The current annual EBIT of ALLO is -$314.49 M
What is the all time high annual EBIT for Allogene Therapeutics?
Allogene Therapeutics all-time high annual earnings before interest & taxes is -$169.74 M
What is Allogene Therapeutics annual EBIT year-on-year change?
Over the past year, ALLO annual earnings before interest & taxes has changed by +$21.04 M (+6.27%)
What is Allogene Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of ALLO is -$66.19 M
What is the all time high quarterly EBIT for Allogene Therapeutics?
Allogene Therapeutics all-time high quarterly earnings before interest & taxes is $1.71 M
What is Allogene Therapeutics quarterly EBIT year-on-year change?
Over the past year, ALLO quarterly earnings before interest & taxes has changed by -$3.91 M (-6.27%)
What is Allogene Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of ALLO is -$275.14 M
What is the all time high TTM EBIT for Allogene Therapeutics?
Allogene Therapeutics all-time high TTM earnings before interest & taxes is -$2.60 M
What is Allogene Therapeutics TTM EBIT year-on-year change?
Over the past year, ALLO TTM earnings before interest & taxes has changed by +$63.24 M (+18.69%)